Loss of p53 and MCT-1 Overexpression Synergistically Promote Chromosome Instability and Tumorigenicity
Authors:
- Ravi KasiappanRKRavi Kasiappan
- Hung-Ju ShihHSHung-Ju Shih
- Kang-Lin ChuKCKang-Lin Chu
- Wei-Ti ChenWCWei-Ti Chen
- Hui-Ping LiuHLHui-Ping Liu
- Shiu-Feng HuangSHShiu-Feng Huang
- Chik On ChoyCCChik On Choy
- Chung-Li ShuCSChung-Li Shu
- Richard DinRDRichard Din
- Jan-Show ChuJCJan-Show Chu
- Hsin-Ling HsuHHHsin-Ling Hsu
Open Access
- 1 April 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 7 (4) , 536-548
Abstract
MCT-1 oncoprotein accelerates p53 degradation by means of the ubiquitin-dependent proteolysis. Our present data show that induction of MCT-1 increases chromosomal translocations and deregulated G2-M checkpoint in response to chemotherapeutic genotoxin. Remarkably, increases in chromosome copy number, multinucleation, and cytokinesis failure are also promoted while MCT-1 is induced in p53-deficient cells. In such a circumstance, the Ras–mitogen-activated protein kinase/extracellular signal-regulated kinase kinase–mitogen-activated protein kinase signaling activity and the expression of metastatic molecules are amplified. Given a p53-silencing background, MCT-1 malignantly transforms normal breast epithelial cells that are satisfactory for stimulating cell migration/adhesion and tumorigenesis. Detailed analyses of MCT-1 oncogenicity in H1299 p53-null lung cancer cells have shown that ectopically expressed MCT-1 advances xenograft tumorigenicity and angiogenesis, which cannot be completely suppressed by induction of p53. MCT-1 counteracts mutually with p53 at transcriptional levels. Clinical validations confirm that MCT-1 mRNA levels are differentially enriched in comparison between human lung cancer and nontumorigenic tissues. The levels of p53 mRNA are comparatively reduced in a subset of cancer specimens, which highly present MCT-1 mRNA. Our results indicate that synergistic promotions of chromosomal imbalances and oncogenic potency as a result of MCT-1 expression and p53 loss play important roles in tumor development. (Mol Cancer Res 2009;7(4):536–48)Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotypeOncogene, 2008
- Oncogenic Ras and Transforming Growth Factor-β Synergistically Regulate AU-Rich Element–Containing mRNAs during Epithelial to Mesenchymal TransitionMolecular Cancer Research, 2008
- Targeting integrin β4 for cancer and anti-angiogenic therapyTrends in Pharmacological Sciences, 2007
- Chromosomal Instability and Supernumerary Centrosomes Represent Precursor Defects in a Mouse Model of T-Cell LymphomaCancer Research, 2007
- Cell cycle kinases in cancerCurrent Opinion in Genetics & Development, 2007
- H‐Ras selectively up‐regulates MMP‐9 and COX‐2 through activation of ERK1/2 and NF‐κB: An implication for invasive phenotype in rat liver epithelial cellsInternational Journal of Cancer, 2006
- Systematic identification and functional screens of uncharacterized proteins associated with eukaryotic ribosomal complexesGenes & Development, 2006
- Oncogenic RAS Induces Accelerated Transition through G2/M and Promotes Defects in the G2 DNA Damage and Mitotic Spindle CheckpointsJournal of Biological Chemistry, 2006
- p53 deficiency exacerbates pleiotropic mitotic defects, changes in nuclearity and polyploidy in transdifferentiating pancreatic acinar cellsOncogene, 2005
- Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cellsCellular Signalling, 2004